HEP-0315

AIO Studien gGmbH is a German non-profit academic research organization and clinical trial sponsor affiliated with the Arbeitsgemeinschaft Internistische Onkologie (AIO) of the German Cancer Society. The organization focuses on the design, coordination, and execution of multicenter clinical trials in the field of medical oncology, particularly for gastrointestinal, hepatobiliary, and thoracic cancers. One of its notable recent projects is the NIFE trial (AIO-YMO HEP-0315), which evaluated nanoliposomal irinotecan (nal-IRI) in combination with 5-fluorouracil and leucovorin as a first-line therapy for advanced cholangiocarcinoma. AIO Studien gGmbH collaborates extensively with pharmaceutical partners like Servier and Ipsen to advance standard-of-care treatments through investigator-initiated trials.